UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net income	$ (2,621)	$ (600)	$ 389	$ (1,429)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization			132	14
Equity-based compensation			1	11
Amortization of right-of-use asset			104	390
Change in fair value of contingent consideration	159	0	295	0
Gain on early lease termination	0	0	(5,974)	0
Gain on settlement of accounts payables	0	0	(191)	0
Loss from sale or disposal of property and equipment	60	0	86	0
Changes in operating assets and liabilities:
Other receivable			1,434	(544)
Prepaid expenses and other current assets			169	415
Other noncurrent assets			(734)	0
Accounts payable			303	(46)
Accrued expenses			106	(32)
Other liabilities			0	(395)
Net cash used in operating activities			(3,880)	(1,616)
Cash flows from investing activities:
Property and equipment			(320)	0
Proceeds from sale of fixed assets			40	0
Acquisition of GPCR Therapeutics USA Inc.			(2,090)	0
Net cash used in investing activities			(2,370)	0
Cash flows from financing activities:
Proceeds from short-term borrowing			0	1,000
Proceeds from common stock offering			1,600	0
Net cash provided by provided by financing activities			1,600	1,000
Net decrease in cash, cash equivalents, and restricted cash			(4,650)	(616)
Cash, cash equivalents, and restricted cash - beginning of period			12,508	2,016
Cash, cash equivalents, and restricted cash - end of period	$ 7,858	$ 1,400	$ 7,858	$ 1,400